Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-2130

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-2130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

This text provides pharmacokinetic information on the effect of renal and hepatic impairment, as well as gender and age, on a certain drug. The geometric mean ratios for Cmax and AUC values are given for mild, moderate, severe, and ESRD renal impairment, as well as for hepatic impairment. Additionally, the effect of gender and age on Cmax and AUC values is also provided. The text is suitable for pharmacologists or healthcare professionals who are interested in the pharmacokinetics of the drug under consideration.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

This appears to be a table related to changes in CYP3A4 inhibitors caused by the administration of Ketoconazole. The table displays data on the geometric mean ratio of the maximum concentration (Cmax) and area under the curve (AUC) for Ketoconazole, with respect to a reference value. However, it is not clear what the reference value is or what the units of measurement are.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

The text describes a graph that shows the estimated proportion of patients with relapse over a period of time. The x-axis represents the time to relapse in days and the y-axis shows the percentage of patients with relapse. The graph compares two treatments: Desvenlafarine Extended-Release Tablets 50mg and a Placebo. The graph shows that the percentage of patients with relapse is lower for Desvenlafarine Extended-Release Tablets at all time points.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

This appears to be a graph showing the estimated proportion of patients with relapse, with the x-axis labeled as "Time to relapse" in days and the y-axis labeled as an estimated percentage of patients. The graph also shows the comparison between Desvenlafaxine Extended-Release Tablets and a placebo, with Desvenlafaxine showing a lower estimated proportion of patients with relapse over time.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

This appears to be a chemical structure diagram consisting of the chemical symbols for two hydrogen atoms, followed by one carbon atom, and finally two oxygen atoms. It likely represents a molecule or compound composed of these atoms.*

FDA Label Image

Label (Lbl713352130)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.